This Article Free Full Text (Free PDF) Free All Versions of this Article: 0269881105056665v1 20/1/119    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (7) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pajonk, F.-G. B. Articles by Seelig, M. A. Search for Related Content PubMed PubMed Citation Articles by Pajonk, F.-G. B. Articles by Seelig, M. A. Social Bookmarking                         What's this?

Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series

Department of Psychiatry and Psychotherapy, The Saarland University Hospitals, Hamburg, Germany, frank.pajonk{at}uniklinik-saarland.de

Anne K. Schwertner

Department of Psychiatry and Psychotherapy, The Saarland University Hospitals, Hamburg, Germany

Marko Alexander Seelig

Department of Psychiatry and Psychotherapy, The Saarland University Hospitals, Hamburg, Germany

To quickly reduce symptoms and to optimize long-term outcome, patients with an acute episode of schizophrenia or mania require prompt treatment intervention. The atypical antipsychotic quetiapine (‘Seroquel’) has been approved for the treatment of schizophrenia and manic episodes associated with bipolar disorder. For patients with acute symptoms such as aggression or agitation, higher doses of quetiapine than the recommended initiation schedule are often required. This report presents the tolerability findings from rapid initiation with high-dose quetiapine for eight patients who were consecutively admitted with acute symptoms of schizophrenia (n 5) or mania (n 3). The results from this case series show that quetiapine treatment could be safely titrated at a more rapid rate and to doses greater than that described in the current prescribing information. For most patients, rapid dose escalation was well tolerated; no serious side effects were observed and vital clinical parameters were unchanged; one patient experienced transient somnolence. In conclusion, these results suggest that rapid dose escalation of quetiapine could be a useful treatment approach for acutely ill patients with schizophrenia and bipolar mania in order to improve acute symptoms and support the need for randomized controlled trials. However, dose adjustments should be considered with respect to each patient’s individual level of tolerability.

Key Words: schizophrenia • mania • acute symptoms • quetiapine • high dose • tolerability

This version was published on January 1, 2006

Journal of Psychopharmacology, Vol. 20, No. 1, 119-124 (2006)
DOI: 10.1177/0269881105056665


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?